Harmony Biosciences Holdings, I (HRMY) Stock Analysis
Temp Headwind edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $30.44, but acceptable to hold if already in. Reasons: Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet.
Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy and expanding into rare epilepsy and neurobehavioral disorders. Net product revenue from WAKIX was $868.5 million in 2025; WAKIX represented 98% of total revenue. The company's core... Read more
Hold if already holding. Not a fresh buy at $30.44, but acceptable to hold if already in. Reasons: Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Quality-value play. Wait for momentum improvement. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Score 6.5/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Harmony Biosciences Holdings, I
Latest news
- Oppenheimer raises Harmony Biosciences stock price target on patent strength - Investing.com UK — Investing.com UK positive
- Harmony Biosciences (HRMY) Is Up 9.7% After New CFO Hire And Reiterated 2026 Guidance – Has The Bull Case Changed? - sim — simplywall.st positive
- AQR Small Cap Multi-Style Fund's Harmony Biosciences Holdings Inc(HRMY) Holding History - GuruFocus — GuruFocus neutral
- Harmony Biosciences Holdings, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:HRMY) 2026-05-13 - Seeking Alp — Seeking Alpha neutral
- Harmony Biosciences Holdings Inc (HRMY) Q1 2026 Earnings Report Preview: What To Expect - GuruFocus — GuruFocus neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductWAKIX98%10-K Item 1A: 'We are substantially dependent on the commercial success of our only approved product, WAKIX.'
- HIGHSupplierBioprojet10-K Item 1A: 'We rely on our license agreements with Bioprojet to provide rights to the core intellectual property relating to pitolisant, and any termination or loss of significant rights under the agreement would adversely affect our development and/or commercialization of pitolisant.'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02MEDIUMSandip Kapadia, CFO, stepping down effective April 14, 2026 to pursue other career opportunities. Glenn Reicin appointed CFO effective same date. Clean handoff with named successor.SEC filing →
- 2026-04-02Item 5.02LOWPeter Anastasiou appointed Senior EVP and COO effective April 2, 2026. In connection with appointment, Anastasiou resigned as Class III Board director, also effective April 2, 2026. No disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $30.44, but acceptable to hold if already in. Reasons: Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Quality-value play. Wait for momentum improvement. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Target $38.60 (+26.8%), stop $28.31 (−7.5%), A.R:R 3.4:1. Score 6.5/10, moderate confidence.
Take-profit target: $38.60 (+26.8% upside). Target $38.60 (+26.8%), stop $28.31 (−7.5%), A.R:R 3.4:1. Stop-loss: $28.31.
Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet; Consecutive earnings misses (3).
Harmony Biosciences Holdings, I trades at a P/E of 12.0 (forward 5.3). TrendMatrix value score: 9.3/10. Verdict: Hold.
17 analysts cover HRMY with a consensus score of 3.8/5. Average price target: $44.
What does Harmony Biosciences Holdings, I do?Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy and expanding into rare...
Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy and expanding into rare epilepsy and neurobehavioral disorders. Net product revenue from WAKIX was $868.5 million in 2025; WAKIX represented 98% of total revenue. The company's core IP is exclusively licensed from Bioprojet under two license agreements.